Depomed, Inc. (NASDAQ:DEPO) will issue its quarterly earnings data after the market closes on Monday, November 6th. Analysts expect the company to announce earnings of $0.12 per share for the quarter.
Depomed (NASDAQ:DEPO) last issued its quarterly earnings data on Monday, August 7th. The specialty pharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.09 by ($0.52). The firm had revenue of $100.00 million for the quarter, compared to analyst estimates of $100.40 million. Depomed had a negative net margin of 26.02% and a negative return on equity of 45.03%. The firm’s revenue for the quarter was down 14.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.27 EPS. On average, analysts expect Depomed to post $-1.36 EPS for the current fiscal year and $-0.6 EPS for the next fiscal year.
Depomed, Inc. (NASDAQ:DEPO) opened at 4.88 on Monday. The firm’s market cap is $307.38 million. The stock has a 50 day moving average of $5.74 and a 200 day moving average of $8.77. Depomed, Inc. has a 12-month low of $4.77 and a 12-month high of $24.00.
COPYRIGHT VIOLATION NOTICE: “Depomed, Inc. (DEPO) Scheduled to Post Quarterly Earnings on Monday” was originally published by Community Financial News and is the sole property of of Community Financial News. If you are reading this story on another website, it was illegally stolen and reposted in violation of United States and international copyright law. The correct version of this story can be accessed at https://www.com-unik.info/2017/10/30/depomed-inc-depo-scheduled-to-post-quarterly-earnings-on-monday.html.
Several research firms have issued reports on DEPO. Royal Bank Of Canada set a $10.00 price target on shares of Depomed and gave the stock a “hold” rating in a report on Friday, October 20th. ValuEngine lowered shares of Depomed from a “sell” rating to a “strong sell” rating in a report on Thursday, September 28th. Janney Montgomery Scott lowered shares of Depomed from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $18.00 to $8.00 in a research note on Tuesday, August 8th. BidaskClub lowered shares of Depomed from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 5th. Finally, Piper Jaffray Companies reiterated a “neutral” rating and issued a $9.00 price objective (down previously from $10.00) on shares of Depomed in a research note on Wednesday, August 9th. Four investment analysts have rated the stock with a sell rating, five have issued a hold rating and three have assigned a buy rating to the stock. Depomed has an average rating of “Hold” and an average target price of $12.74.
Depomed, Inc is a specialty pharmaceutical company. The Company focuses on pain and other central nervous system (CNS) conditions. Its products include NUCYNTA ER (tapentadol extended release tablets), NUCYNTA IR (NUCYNTA) (tapentadol), Gralise (gabapentin), CAMBIA (diclofenac potassium for oral solution), Zipsor (diclofenac potassium) and Lazanda (fentanyl).
What are top analysts saying about Depomed Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Depomed Inc. and related companies.